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Background: Severe eczema in young children is associated with an increased risk of developing asthma and
rhino-conjunctivitis. In the general population, however, most cases of eczema are mild to moderate. In an
unselected cohort, we studied the risk of current asthma and the co-existence of allergy-related diseases at 6 years
of age among children with and without eczema at 2 years of age.
Methods: Questionnaires assessing various environmental exposures and health variables were administered at 2
years of age. An identical health questionnaire was completed at 6 years of age. The clinical investigation of a
random subsample ascertained eczema diagnoses, and missing data were handled by multiple imputation analyses.
Results: The estimate for the association between eczema at 2 years and current asthma at 6 years was OR=1.80
(95% CI 1.10-2.96). Four of ten children with eczema at 6 years had the onset of eczema after the age of 2 years,
but the co-existence of different allergy-related diseases at 6 years was higher among those with the onset of
eczema before 2 years of age.
Conclusions: Although most cases of eczema in the general population were mild to moderate, early eczema was
associated with an increased risk of developing childhood asthma. These findings support the hypothesis of an
atopic march in the general population.
Trial registration: The Prevention of Allergy among Children in Trondheim study has been identified as
ISRCTN28090297 in the international Current Controlled Trials database
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The atopic march is a term used to describe the rela-
tionship between allergy-related diseases, starting with
food allergy and eczema in early childhood, and the sub-
sequent development of asthma and rhino-conjunctivitis.
An association between eczema and asthma in child-
hood has been documented in several studies, and se-
vere eczema is associated with an increased tendency to
produce immunoglobulin E (IgE) and developing asthma
[1-7]. The nature of the relationship between eczema
and asthma has, however, been debated. Although these
diseases share some genetic and environmental risk* Correspondence: marit.saunes@ntnu.no
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reproduction in any medium, provided the orfactors, it has been argued that eczema and asthma are
unrelated and that the progression of eczema to asthma
is due to the co-manifestation of eczema and wheezing
early in life [3,6]. On the other hand, plausible biological
pathways have been described, with eczema as the first
step in a progressive atopic march leading to asthma
and/or rhino-conjunctivitis [8,9]. It has also been argued
that the atopic march is restricted to males only [1]. A
defective skin barrier due to mutations in the gene en-
coding profilaggrin/filaggrin (FLG) is associated with
increased trans-epidermal water-loss, dry skin, itching
and eczema [10]. Studies on FLG mutations have not,
however, found any association with FLG mutations and
asthma/rhino-conjunctivitis in children who did not
have eczema.
These findings suggest different phenotypes for both
asthma and eczema [11-13].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cross-sectional data, high-risk or hospitalised patients,
population-based studies with prospective designs are
warranted [3,5,6,14,15]. The aim of the present study was
to prospectively investigate the association between a his-
tory of eczema at 2 years of age and current asthma at 6
years of age in a general population. We also aimed to de-
termine the prevalence of allergy-related diseases at 6
years of age according to eczema status at 2 years of age.
Methods
The Prevention of Allergy among Children in Trond-
heim (PACT) study is a comprehensive, controlled, pri-
mary intervention study of allergy-related diseases in
Trondheim, central Norway. The study is described in
detail elsewhere [16]. Briefly, the control cohort included
pregnant women and parents with their young children
at ages 6 weeks, 1 year, 2 years and 6 years attending or-
dinary scheduled appointments with GPs, midwives or
health-workers. The inclusion of 2-year-olds started on
September 1st of 2000 and closed on March 31st of 2005;
the inclusion of 6-year-olds started on September 1st of
2000 and closed on December 31st of 2008. In the
present study, children from the PACT control cohort
with cross-sectional data at 2 years were followed-up at
the age of 6 years. In addition, we used information on
sensitisation from a random subsample of children eval-
uated clinically at 2 years of age.
Study variables
Parents of children at age 2 (baseline) were given ques-
tionnaires concerning environmental exposures and the
family history of different allergy-related diseases in the
parents and siblings. A detailed questionnaire concern-
ing the child’s health, with an emphasis on allergy-
related diseases, was also administered. An identical
health questionnaire was administered when the child
was 6 years of age. The questions were adapted from the
International Study of Asthma and Allergies in Child-
hood (ISAAC) study to fit both age groups.
Both questions “Has your child ever had eczema?” and
“Has your child ever had an itchy rash which was com-
ing and going for at least 6 months?” had to be answered
positively to obtain the designation of “history of ec-
zema” at 2 years of age. To identify children who had
current eczema at 6 years of age, the two former ques-
tions were combined with “Has your child during the
last 12 months used any kind of medication, ointment,
cream, tablets or herbal medicines against eczema?” A
history of asthma was denoted by a positive answer to
the question “Has your child ever been diagnosed as
having asthma by a doctor?” To obtain current asthma
status, the former question was combined with a positive
answer to “Has the child during the last 12 months usedtablets, inhalation medications or other treatments for
wheezing, tightness in the chest or asthma?”
The presence of wheezing was determined by a posi-
tive answer to both questions “Has your child ever had
whistling in the chest?” and “Has your child ever had
episodes of wheezing or tightness in the chest?”
Positive answers to the question “Has your child ever
had hay fever, sneezing or itchy-watery eyes” defined a
history of rhino-conjunctivitis.
A history of an allergy test was defined as an affirma-
tive response to the question “Has your child ever been
allergy tested by skin prick test or blood test?” A positive
allergy test was present if the child’s parent(s) reported a
positive reaction to at least one allergen.
“Atopy in the family” was registered as present if the
child’s mother, father or any siblings had answered “yes”
to one of several questions regarding asthma, eczema
and allergic rhino-conjunctivitis.
The term “Homeowner” was used as a proxy for socio-
economic status and was based on the question “Do
you/your family own your apartment/house”.
The random subsample
From March 2001 to September 2002, a randomly
sampled group of 720 pregnant women from the same
control cohort described above were invited to attend a
sub-study of PACT [17] . Their children were invited to
a clinical examination at 2 years of age, including an as-
sessment for eczema according to the United Kingdom
Working Party (UKWP) diagnostic criteria. Disease se-
verity was scored by the Scoring of Atopic Dermatitis
(SCORAD) index and sensitisation was evaluated by
standard prick test (SPT) and specific IgE (sIgE) mea-
surements [14].
For SPT testing, the following standardised extracts
from SoluprickW allergens (ALK Albello, Denmark) were
used: mite (Dermatophagoides pteronyssinus), mould
(Cladosporium herbarum), cat and dog dander, birch,
timothy (grass) and mugwort pollens, hen’s egg white,
codfish, hazelnut and peanut. For cow’s milk fresh
skimmed milk was used. In addition, two positive hista-
mine controls (Histamine 10mg/ml) and one diluents-
negative control (NaCl) were applied on the volar
surface of the child’s forearms. A mean wheal diameter
of at least 3 mm larger than the negative control was
considered a positive test.
Sera from venous blood samples were analysed for
sIgE using assays testing for the same allergens as the
SPTs. Venous sampling was attempted only once. The
sIgE analyses were carried out in the immunology la-
boratory at St Olavs University Hospital, Trondheim,
using the ImmuliteW 2000 Allergen-specific IgE system
(Siemens Medical Solutions Diagnostics, Deerfield, IL,
U.S.A.). A sIgE ≥0.35 kUL-1 was considered positive.
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had a positive SPT or a positive sIgE.Statistics
Baseline characteristics as well as allergy-related diseases
are described as prevalences with 95% confidence inter-
vals (CI) for dichotomous variables.
Multivariable, logistic regression models were used to
estimate the adjusted associations between a history of
eczema at 2 years and current asthma at 6 years. Eczema
and the age of eczema onset were used as explanatory
variables. The age of eczema onset was divided in tertiles
(0–3 months, 4–12 months, 13 months or older), and all
other explanatory variables in the model were dichoto-
mised. The possible confounding factors were identified
by a priori knowledge, and in the final models, adjust-
ments were made for sex, atopy in the family, wheezing,
homeowner status and a smoking mother. Interaction
on the multiplicative level was tested between eczema
and sex and between eczema and wheezing using the
likelihood ratio test. Children with a history of doctor-
diagnosed asthma at age 2 years were excluded from the
follow-up analyses. In addition, follow-up analyses
excluding both children with doctor-diagnosed asthma
and children who had ever experienced wheezing at age
2 years were performed.Missing data analysis
Due to the large amount of missing data, we used mul-
tiple imputations (MI) to assess the potential impact of
missing data in the regression analyses. We assumed that
data were missing at random given the results from the
observed data, and we used chained equations (regression
switching) with 50 sets of imputations to impute missing
values as implemented in the STATA’s ICE command. The
following predictor variables reported at 2 years were
included in the imputation model: eczema, age in tertiles,
siblings, atopy in the family, a cat in the household, symp-
toms of wheezing/whistling in the chest, symptoms of hay
fever, history of hospitalisation for any allergy-related dis-
eases, homeowner status, smoking mother/father and sensi-
tisation. In addition, the outcome variable, current asthma
at 6 years, was included. Because reported sensitisation was
not considered missing at random, sensitisation-data from
the subsample, where all of the randomly selected partici-
pants included were tested regardless of the presence of
disease symptoms, were used as predictors in the ICE com-
mand. A multiplicative interaction term between eczema
and sensitisation was also included in the predictive ICE
command and tested in the final models. For each outcome
variable, a separate MI dataset was created, and resulting
estimates were combined by the MIM command in
STATA. To study the association between a history ofeczema at 2 years and current asthma at 6 years, logistic re-
gression analyses were performed on the MI dataset.
In addition to the multiple imputation approach, we also
performed analyses based on individuals with complete data.
All data were analysed using STATA for Windows
(version 11, College Station, Texas, USA).Ethics
All parents signed a written consent form to participate
in the PACT study. The Regional Committee for Medical
Research Ethics and the Norwegian Data Inspectorate
Board approved the study (Ref 120–2000) (Ref 2003/
953-3 KBE/-).
The PACT study has been registered in Current Con-
trolled Trials database (ISRCTN28090297).Results
By March 31st of 2005, 4780 parents had completed the
baseline questionnaires at their child’s second year of
age, and by April of 2009, 2192 (46%) of these had also
returned the health questionnaire when their children
turned 6. Comparison of the baseline characteristics of
the children with follow-up data at 6 years (n=2192) and
children with no follow-up data (n=2588) are shown in
Table 1. Apart from more “smoking mothers” and fewer
“homeowners” among children with no follow-up data at
6 years, compared to children with follow-up data at 6
years, the two groups were comparable at baseline. In
addition, the mothers of children with follow-up data
were slightly older at delivery (mean age 29.8, ± 4.50 SD
vs. 28.9, ± 4.79 SD). Among children with follow-up data
at 6 years, the prevalence of eczema, asthma and wheez-
ing at 2 years was 17.8% (95% CI 16.2-19.5), 6.5% (95%
CI 5.5-7.6) and 25.3% (95% CI 23.5-27.2), respectively.
The corresponding reported prevalences for children
with no follow-up data showed only small and insignifi-
cant differences from these numbers (Table 1).
In Table 2, we compared the estimated prevalence of
allergy-related diseases at 2 years of age among those
with available data at baseline with the estimated preva-
lence using multiple imputations; no substantial differ-
ences were found. We also compared the estimated
prevalence of allergy-related diseases among 6-year-olds
with follow-up data to the estimated prevalence found
using multiple imputations. The prevalence of asthma
and rhino-conjunctivitis at 6 years of age tended to be
higher using multiple imputation, but the differences
were small (Table 3).
More than one-half (56%) of the children with a his-
tory of eczema at 2 years did not report current eczema
at age 6 years (Table 4). Approximately 42% of those
with eczema at age 6 years had their first appearance of
eczema after 2 years of age.
Table 1 Baseline characteristics and prevalence of allergy-related diseases at 2 years of age
Children with follow-up data at 6 years (N=2192)a Children without follow-up data at 6 years (N=2588)a
n/N % 95% CI n/N % 95% CI
Characteristics
Male sex 1080/2192 49.3 47.2-51.4 1309/2586 50.6 48.7-52.6
Sibling(s) 1531/2160 70.9 68.9-72.8 1734/2554 67.9 66.0-69.7
Atopy in the family 1474/2157 68.3 66.3-70.3 1733/2543 68.1 66.3-70.0
Breastfed ≥ 3 months 1862/1981 94.0 92.9-95.0 2191/2334 93.9 92.8-94.8
Ever antibiotics 1008/2181 46.2 44.1-48.3 1188/2578 46.1 44.1-48.0
Dog at home 163/2002 8.1 7.0-9.4 202/2364 8.5 7.4-9.7
Cat at home 158/2002 7.9 6.7-9.2 239/2364 10.1 8.9-11.4
Homeowner 1973/2159 91.4 90.1-92.5 2145/2552 84.1 82.6-85.5
Smoking mother 381/2124 17.9 16.3-19.6 548/2503 21.9 20.3-23.6
Smoking father 346/1944 17.8 16.1-19.6 461/2244 20.5 18.9-22.3
Allergy related diseasesb
Eczema 386/2169 17.8 16.2-19.5 402/2554 15.7 14.3-17.2
Doctor-diagnosed asthma 143/2191 6.5 5.5-7.6 194/2587 7.5 6.5-8.6
Wheezing 554/2189 25.3 23.5-27.2 701/2585 27.1 25.4-28.9
Rhino-conjunctivitis 119/2182 5.4 4.5-6.5 160/2564 6.2 5.3-7.2
Allergy test performed 462/2185 21.1 19.4-22.9 543/2569 21.1 19.6-22.8
Sensitisation (any) 223/1973 11.3 9.9-12.8 272/2323 11.7 10.4-13.1
aNumbers of missing data varies for different variables.
bEstimates of ever having the disease.
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prevalence of eczema at 2 years. Overall, however, boys
reported significantly more asthma than girls both at 2
years (5.4% vs. 8.7%, p<0.001) and at 6 years (6.4% vs.
11.2%, p<0.001).
Children with eczema at 2 years reported more asthma
at both 2 and 6 years compared to those without
eczema. The co-existence of eczema and rhino-
conjunctivitis, eczema and asthma and asthma and
rhino-conjunctivitis at 6 years of age among children
with eczema at 2 years was 15%, 4.9% and 4.9%, respec-
tively. The corresponding numbers for those without
eczema at 2 years were all less than 1% (Figure 1).
Among children with follow-up data at 6 years
(complete case analysis), the adjusted odds ratio be-
tween eczema at 2 years and current asthma at 6 yearsTable 2 Prevalence of allergy-related diseases and sensitisatio
Baseline
n %
Eczema (ever) 788/4723 16.7
Asthma (ever) 337/4778 7.1
Wheezing (ever) 1255/4774 26.3
Sensitiseda — —
aOnly children in the subsample were allergy tested.was 1.95 (95% CI 1.07-3.54) (Table 5). When the age of
onset for eczema was included in the model, an onset
before four months of age (first tertile) was significantly
associated with asthma at 6 years, adjusted OR= 4.51
(95% CI 1.73-11.72) (Table 6). We found no basis for a
multiplicative interaction between eczema and sex
(p=0.83) or eczema and wheezing (p=0.13) for risk of
asthma at 6 years.
The analysis using multiple imputations provided
nearly the same associations as the complete case ana-
lysis. When information on sensitisation was included in
the model, no substantial change in the association
between eczema and asthma was found (Table 5). We
repeated the analysis after removing all children who
reported doctor diagnosed asthma (ever) at 2 years and
children with wheezing (ever) at 2 years. The associationn in children at 2 years of age
Multiple imputation (N=4780)





Table 3 Prevalence of allergy-related diseases in children at 6 years of age
Children with follow-up data Multiple imputation(N=4780)
n % 95% CI % 95% CI
Eczema (current) 295/2171 13.6 12.2-15.1 14.0 12.5-15.5
Asthma (current) 121/2192 5.5 4.6-6.6 8.0 6.6-9.3
Rhino-conjunctivitis (ever) 255/2178 11.7 10.4-13.1 14.7 12.9-16.5
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still significant with OR=2.06 (95% CI 1.09-3.90) (data
not shown).
In the model with age of eczema onset categorised in
tertiles, the association between age of eczema onset
during the first tertile (before 4 months of age) and
current asthma at 6 years did not indicate a clear trend
or pattern for the age onset eczema and risk of asthma
(Table 6). We found no evidence for a multiplicative
interaction between eczema and sensitisation (p=0.70).
Boys had a slightly higher risk than girls of developing
asthma, but the differences were not significant.The random subsample
At age 2 years, 441 of 720 randomly selected children
from the control cohort included since pregnancy were
eligible for follow-up. Of these, 390 children (88%) parti-
cipated in a clinical examination. The prevalence of a
history of eczema, doctor-diagnosed asthma and wheez-
ing reported in questionnaires at 2 years was 21.0%,
8.8% and 23.5%, respectively. The prevalence of clinically
investigated eczema according to the UKWP diagnostic
criteria was 15.9%.
An allergy test, either a SPT or a sIgE, was performed
in 91% of the children. Of those with UKWP-Eczema,
some 22.4% (95% CI 12.5-35.3.4) had a positive test,
while some 14.5% (95% CI 10.7-19.0) of those without
UKWP-Eczema tested positive (p=0.7).Table 4 Prevalence of allergy-related diseases reported at 2 a
Reported at 2 years
Asthma Wheezing
n % 95% CI n % 95% CI
Reported eczema 2 yrs
Total (n=386) 39 10.1 7.3-13.6 134 34.7 30.0-39.7
Boys (n=200) 27 13.5 9.1-19.0 76 38.0 31.2-45.1
Girls (n=186) 12 6.4 3.4-11.0 58 31.2 24.6-38.4
Reported no eczema 2 yrs
Total (n=1783) 102 5.7 4.7-6.9 414 23.2 21.3-25.3
Boys (n=863) 65 7.5 5.9-9.5 222 25.7 22.8-28.8
Girls (n= 920) 37 4.0 2.8-5.5 192 20.9 18.3-23.6
aIn children with eczema at 2 years: 22/41 children reporting asthma at 6 years also
bIn children without eczema at 2 years: 42/79 children reporting asthma at 6 yearsDiscussion
In this large, prospective study from the general popula-
tion, we found a strong association between eczema at
age 2 years and asthma at age 6 years. Asthma was
reported more often among boys than girls, regardless of
eczema status. Four out of ten children with eczema at
age 6 had the onset of their eczema after 2 years of age,
but the co-existence of allergy-related diseases reported
at 6 years was higher among children with an onset of
eczema before 2 years of age. More than one-half of the
children with eczema during the first two years of life no
longer had eczema when they turned 6 years.
This comprehensive study was conducted in the pri-
mary health care setting. However, as only close to half
of the included children had follow-up data at 6 years,
there is a possibility of selection bias [16]. The design of
the PACT study is that of multiple, yearly, cross-
sectional cohorts of children consecutively included
from the year 2000. During the inclusion period, we
have observed a decline in the number of participants
over time. However, a non-participant study carried out
among 391 parents who consecutively attended maternal
postnatal care revealed no substantial differences in age,
education, familial allergy-related diseases and smoking
behaviour when comparing participants and non-
participants [16]. This trend is also supported by the
baseline data and clinical characteristics among those
children with follow-up data at 6 years compared with
children with no follow-up data at 6 years. Apart fromnd 6 years by eczema-status and sex
Reported at 6 years
Eczema Asthma Rhino-conjunctivitis
n % 95% CI n % 95% CI n % 95% CI
170 44.0 39.0-49.2 41a 10.6 7.7-14.1 105 27.2 22.8-31.9
81 40.5 33.6-47.7 24 12.0 7.8-17.3 57 28.5 22.4-35.3
89 47.8 40.5-55.3 17 9.1 5.4-14.2 48 25.8 19.7-32.7
123 6.9 5.8-8.2 79b 4.4 3.5-5.5 148 8.3 7.1-9.7
49 5.7 4.2-7.4 53 6.1 4.6-8.0 88 10.2 8.3-12.4
74 8.0 6.4-10.0 26 2.8 1.9-4.1 60 6.5 5.0-8.3
reported asthma at 2 years.
also reported asthma at 2 years.
Figure 1 Co-existence of allergy-related diseases reported at age 6 years among children with (A) and without (B) eczema at 2 years
of age.
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owners and more smoking mothers among children
without available data at 6 years, only minor differences
were found. This socioeconomic difference between par-
ticipants and non-participants is a well-known challenge
in population-based studies, and has also been reported
by others [7,18]. The low inclusion rate is most likely
due to low inclusion activity among GPs, health visitors
and midwives and is not likely a consequence of self-
selection among parents and children.
Another possible limitation to the study is the use of
questionnaires and parental reporting without a clinical
verification for some of the diagnoses. The question-
naires are from the ISAAC study, and for the 2-year-
olds, we adapted them to fit with this particular
age-group. We have validated the eczema diagnoses
among the 2-year-olds against the UKWP diagnostic cri-
teria in another study [14] and the results indicate that
the prevalence of eczema in this age-group may be over-
estimated when self-reported. The reliability of some of
the questions regarding health has, however, been tested,
and reported doctor-diagnosed asthma and the informa-
tion obtained from medical records showed excellent
agreement [19]. In addition, mother-reported use ofTable 5 Adjusted associations between reported eczema at a
Complete caseb (N=2192)a Multiple im
OR 95% CI OR
Eczema 1.95 1.07-3.54 1.92
Male sex 1.70 0.96-3.00 1.20
Atopy in family 2.30 1.06-4.96 1.84
Wheezing 3.61 2.06-6.31 2.71
Sensitisation (any) — — —
aNumbers of missing data varies for different variables.
bAdjusted for homeowner, smoking mother, male sex, atopy in family and wheezin
cAdjusted for b plus sensitisation.anti-asthmatic medications during the previous year
among 7-year-old children has been shown to be highly
valid [20]. The questions on rhino-conjunctivitis have, to
the best of our knowledge, not been validated for 2-year-
olds, and due to the high rate of infections with symp-
toms resembling rhino-conjunctivitis in this age group,
the prevalence of rhino-conjunctivitis reported at 2 years
must be interpreted with caution.
In addition to the early manifestation of eczema, it is
commonly believed that the severity of eczema, male
sex, early wheezing, heredity and sensitisation are pos-
sible risk factors for the development of childhood
asthma. We used information from the clinical investiga-
tive subsample, in which 91% of the children were tested
either by SPT or blood sample, regardless of the pres-
ence of symptoms, to conduct multiple imputations on
missing sensitisation data. In doing so, the sensitisation
estimate is less precise. Another limitation regarding
sensitisation is the fact that we have only tested the chil-
dren once, at the age of 2 years. We might therefore
have missed the children with transient sensitisation be-
fore this age. In addition, there is also a possibility that
children are sensitised for allergens not tested for, such
as wheat and soybean.ge 2 years and current asthma at 6 years
putationb (N=4780) Multiple imputationc (N=4780)







Table 6 Adjusted associations between the eczema age of onset at 2 years and current asthma at 6 years
Complete caseb (N=2192)a Multiple imputationb (N=4780) Multiple imputationc (N=4780)
OR 95% CI OR 95% CI OR 95% CI
Age of eczema onset in tertilesd
0-3 months 4.51 1.73-11.72 2.18 1.03-4.61 1.98 0.91-4.28
4-12 months 1.21 0.27-5.35 1.40 0.61-3.19 1.33 0.58-3.04
≥13 months 2.94 0.82-10.53 2.11 0.72-6.16 2.05 0.69-6.07
Sex 1.49 0.81-2.74 1.29 0.83-2.00 1.27 0.81-2.01
Atopy in family 2.46 1.08-5.62 1.81 0.99-3.31 1.73 0.92-3.23
Wheezing 4.98 2.72-9.13 2.62 1.55-4.43 2.59 1.52-4.41
Sensitisation (any) — — — — 2.19 0.77-6.20
aNumbers of missing data varies for different variables.
bAdjusted for homeowner, smoking mother, male sex, atopy in family and wheeze.
cAdjusted for b plus sensitisation.
dReference group: children with no eczema during the first2 years of life.
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cipants, the unselected population, the prospective de-
sign, the random clinical subsample at baseline and the
validation of several of the questions.
The prevalence of allergy-related diseases among 6-
year-olds has been widely documented through the
ISAAC study [21]. The 12-month prevalence for eczema
in phase III of the study in Sweden, Germany and the
UK was 19.5%, 7.9% and 16.0%, respectively. Our finding
of 13.6% is in between the prevalence reported in Ger-
many and the U.K. but, surprisingly, is much lower than
in Sweden. The estimated asthma prevalence of 5.5% is
lower than in all three countries (10.2%, 12.8% and
20.9%, respectively), whereas the prevalence of rhinitis in
our study is somewhat higher. The prevalence of ec-
zema, asthma and rhino-conjunctivitis in our cohort of
6-year-olds are, however, well in line with the prevalence
found in a Danish birth cohort among children of the
same age [22].
Whether eczema is a true risk factor for asthma and
rhino-conjunctivitis has been debated, and the relation-
ship between the different allergy-related disorders is
unclear. A population-based, longitudinal birth cohort
study from the U.K. found that impairment in the skin
barrier due to mutations in the FLG gene was associated
with an increased risk of eczema, both atopic and non-
atopic [13]. In addition, patients with these mutations
had more persistent eczema. FLG mutations were also
associated with an increased risk of asthma, but only
when co-existing with eczema [9,13]. Suggestions were
made by the authors that the sub-stratification of ec-
zema based on FLG status could identify those children
who might benefit from early therapeutic intervention.
We did not, however, have the option of FLG testing for
the children participating in this study.
We found that only twenty percent of children with
eczema at 2 years were sensitised, whereas others havefound sensitisation among children in this age group to
be approximately one-third [23]. It has been hypothe-
sised that the course of the disease is different for those
with sensitisation as opposed to those without sensitisa-
tion, and that rather than a progressive atopic march,
there are different phenotypes of eczema leading to
asthma [3,24]. Others have found that FLG mutations
with co-existing eczema increase the risk for asthma and
hay-fever without an obligate presence of concurrent
sensitisation [13]. Our results show an increased risk of
asthma at age 6 years among children with eczema at 2
years compared to children without eczema at 2 years,
regardless of sensitisation.
Conclusions
Although most cases of eczema in primary health care are
mild to moderate, the findings from this study support the
hypothesis of an atopic march in the general population.
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